<DOC>
	<DOCNO>NCT00410462</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , brostallicin doxorubicin , work different way stop growth tumor cell , either kill cell stop dividing . PURPOSE : This randomized phase II trial study side effect well brostallicin doxorubicin work first-line therapy treat patient relapse , refractory , metastatic soft tissue sarcoma .</brief_summary>
	<brief_title>Brostallicin Doxorubicin First-Line Therapy Treating Patients With Relapsed , Refractory , Metastatic Soft Tissue Sarcoma</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine activity safety brostallicin v doxorubicin hydrochloride first-line therapy patient relapse , refractory , metastatic soft tissue sarcoma . OUTLINE : This randomize , multicenter study . Patients stratify accord participate age ( young 60 year vs 60 year ) . Patients randomize 1 2 treatment arm . - Arm I : Patients receive brostallicin IV 10 minute day 1 . - Arm II : Patients receive doxorubicin hydrochloride IV 10 minute day 1 . In arm , treatment repeat every 3 week 6 course absence disease progression unacceptable toxicity . After completion study treatment , patient follow 30 day every 12 week thereafter . PROJECTED ACCRUAL : A total 108 patient accrue study .</detailed_description>
	<mesh_term>Sarcoma</mesh_term>
	<mesh_term>Intestinal Neoplasms</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically cytologically confirm high intermediategrade malignant soft tissue sarcoma* 1 follow cellular type : Adipocytic ( e.g. , liposarcoma dedifferentiate , myxoid/round cell , pleomorphic , mixedtype , otherwise specify ) Fibroblastic ( e.g. , adult fibrosarcoma , myxofibrosarcoma , sclerosing epithelioid fibrosarcoma ) Socalled fibrohistiocytic ( e.g. , pleomorphic malignant fibrous histiocytoma [ MFH ] , giant cell MFH , inflammatory MFH ) Leiomyosarcoma Malignant glomus tumor Skeletal muscle ( e.g. , rhabdomyosarcoma , alveolar , pleomorphic ) Vascular ( e.g. , epithelioid hemangioendothelioma angiosarcoma ) Uncertain differentiation ( e.g. , synovial , epithelioid , alveolar soft part , clear cell , desmoplastic small round cell , extrarenal rhabdoid , malignant mesenchymoma , perivascular epithelioid cell tumor [ PEComa ] , intimal sarcoma ) Malignant peripheral nerve sheath tumor Malignant solitary fibrous tumor Undifferentiated soft tissue sarcoma otherwise specify Other type sarcoma approve study coordinator NOTE : *Includes malignant tumor nonorgan origin skin uterine leiomyosarcoma The following tumor type exclude : Embryonal rhabdomyosarcoma Chondrosarcoma Osteosarcoma Ewing tumors/primitive neuroectodermal tumor ( PNET ) Gastrointestinal stromal tumor Dermatofibrosarcoma protuberans Inflammatory myofibroblastic sarcoma Neuroblastoma Malignant mesothelioma Mixed mesodermal tumor uterus Relapsed , refractory , and/or metastatic disease incurable surgery radiotherapy Measurable disease Must formalin fix paraffinembedded tumor block representative hematoxylin/eosin slide available histological central review No symptomatic know CNS metastases PATIENT CHARACTERISTICS : At least 60 year age OR ≥ 18 year age patient suitable intensive combination chemotherapy treatment WHO performance status 01 Absolute neutrophil count &gt; 2,000/mm³ Platelet count &gt; 100,000/mm³ Bilirubin ≤ 1.5 time upper limit normal ( ULN ) AST ALT ≤ 2.5 time ULN Alkaline phosphatase ≤ 2.5 time ULN Creatinine clearance ≥ 60 mL/min No serious cardiac illness within past 6 month , include , limited following : History document congestive heart failure Highrisk uncontrolled arrhythmias Angina pectoris require antianginal medication Clinically significant valvular heart disease Evidence transmural infarction ECG Poorlycontrolled hypertension ( e.g. , systolic blood pressure [ BP ] &gt; 180 mm Hg diastolic BP &gt; 100 mm Hg ) Normal 12lead ECG LVEF normal MUGA echocardiogram No malignancy within past 3 year except adequately treat basal cell squamous cell skin cancer carcinoma situ cervix breast No serious and/or unstable medical condition , illness , lab abnormality would preclude study participation No psychiatric illness familial , social , geographical condition would preclude study compliance No active uncontrolled infection No known AIDS positivity Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : No prior chemotherapy regimen advance metastatic disease ( neoadjuvant adjuvant therapy allow ) No concurrent sargramostim ( GMCSF ) except case febrile neutropenia No concurrent anticancer therapy investigational agent , include follow : Chemotherapy Biological response modifier Hormone therapy Immunotherapy No concurrent clinical treatment trial participation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2010</verification_date>
	<keyword>recurrent adult soft tissue sarcoma</keyword>
	<keyword>stage IV adult soft tissue sarcoma</keyword>
	<keyword>adult liposarcoma</keyword>
	<keyword>adult fibrosarcoma</keyword>
	<keyword>adult malignant fibrous histiocytoma</keyword>
	<keyword>adult leiomyosarcoma</keyword>
	<keyword>adult rhabdomyosarcoma</keyword>
	<keyword>adult alveolar soft-part sarcoma</keyword>
	<keyword>adult malignant mesenchymoma</keyword>
	<keyword>adult angiosarcoma</keyword>
	<keyword>adult epithelioid sarcoma</keyword>
	<keyword>adult neurofibrosarcoma</keyword>
	<keyword>adult synovial sarcoma</keyword>
	<keyword>recurrent uterine sarcoma</keyword>
	<keyword>stage IV uterine sarcoma</keyword>
	<keyword>ovarian sarcoma</keyword>
	<keyword>small intestine leiomyosarcoma</keyword>
	<keyword>recurrent small intestine cancer</keyword>
</DOC>